 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
|
|
|
|
Phase IV
|
|
|
|
GERCOR-TAUROX
SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
| |
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
FRE-FNCLCC-ACCORD-11/0402
EU-20512, NCT00112658
|
|
| |
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
SGI-RUB-048
NCT00113256
|
|
| |
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
|
|
|
|
Phase III, Phase II
|
|
|
|
AMT/P2CA/001
LC003AURON2005, NCT00332280
|
|
| |
Efficacy Study of Endoscopic Ultrasonography (EUS)-Guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas
|
|
|
|
Phase III, Phase II
|
|
|
|
AMC0183
NCT00689715
|
|
| |
Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head
|
|
|
|
Phase III, Phase II
|
|
|
|
NNR-02
NCT00753441
|
|
| |
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
CONKO 004
CCT-NAPN-16752, NCT00785421
|
|
| |
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
|
|
|
|
Phase III
|
|
|
|
GV-001.004
NCT00051467
|
|
| |
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
|
|
|
Phase III
|
|
|
|
CRUK-TELOVAC-V4
EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
|
|
| |
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
|
|
|
|
Phase III
|
|
|
|
EFC6596
XRP9881, NCT00417209
|
|
